上海交通大学学报（医学版）

›› 2010, Vol. 30 ›› Issue (1): 104-.

• 综述 • 上一篇    下一篇

过氧化物酶体增殖物激活受体-γ与肾脏纤维化的研究进展

卢 颖, 综述；王伟铭, 审校   

  1. 上海交通大学 医学院附属瑞金医院肾脏科, 上海 200025
  • 出版日期:2010-01-26 发布日期:2010-01-26
  • 通讯作者: 王伟铭, 电子信箱: wweiming@medmail.com.cn。
  • 作者简介:卢 颖（1984—）, 女, 硕士生；电子信箱: luying2008bj@sjtu.edu.cn。

Research advances in peroxisome proliferator activated receptor-gamma and renal fibrosis

LU Ying, reviewer；WANG Wei-ming, reviser   

  1. Department of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China
  • Online:2010-01-26 Published:2010-01-26

PDF (PC)

1385

摘要：

慢性肾脏病发展至终末期可表现为肾小球硬化和（或）肾间质纤维化。有效抑制肾脏纤维化可显著延缓慢性肾脏病的进展。过氧化物酶体增殖物激活受体（PPARs）是配体激活的核转录因子超家族成员。PPAR-γ为PPARs的表型之一，在抑制肾脏纤维化方面的作用已成为当前研究的热点。文章就PPAR-γ及激动剂延缓肾脏纤维化研究新进展进行综述。

关键词: 过氧化物酶体增殖物激活受体-γ, 慢性肾脏病, 肾小球硬化, 肾间质纤维化

Abstract:

The end stage of chronic renal diseases is characterized by glomerular sclerosis and interstitial fibrosis. Studies have revealed that effective amelioration of renal fibrosis can significantly delay the progression of chronic renal diseases. Peroxisome proliferator activated receptors (PPARs) are ligand-activated nuclear transcriptional factors of the nuclear hormone receptor superfamily, and PPAR-γ is one of the phenotypes of PPARs. The effect of PPAR-γ on inhibiting renal fibrosis has become a hot spot. In this article the research advances of PPAR-γ in amelioration of renal fibrosis are reviewed.

Key words: peroxisome proliferator activated receptor-γ, chronic kidney disease, glomerular sclerosis, renal interstitial fibrosis